Migdal Insurance & Financial Holdings Ltd. increased its stake in Boston Scientific Co. (NYSE:BSX) by 3,090.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,020 shares of the medical equipment provider’s stock after acquiring an additional 3,894 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Boston Scientific were worth $131,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Global X Management Co. LLC lifted its holdings in Boston Scientific by 19.5% in the 1st quarter. Global X Management Co. LLC now owns 39,568 shares of the medical equipment provider’s stock valued at $1,081,000 after purchasing an additional 6,443 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Boston Scientific by 6.6% in the 1st quarter. Wells Fargo & Company MN now owns 12,730,496 shares of the medical equipment provider’s stock valued at $347,797,000 after purchasing an additional 784,825 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in Boston Scientific by 2.0% in the 1st quarter. Daiwa Securities Group Inc. now owns 407,774 shares of the medical equipment provider’s stock valued at $11,140,000 after purchasing an additional 7,960 shares in the last quarter. Dupont Capital Management Corp lifted its holdings in Boston Scientific by 739.0% in the 1st quarter. Dupont Capital Management Corp now owns 163,708 shares of the medical equipment provider’s stock valued at $4,473,000 after purchasing an additional 144,196 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI lifted its holdings in Boston Scientific by 52.8% in the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 31,742 shares of the medical equipment provider’s stock valued at $867,000 after purchasing an additional 10,967 shares in the last quarter. Institutional investors own 89.39% of the company’s stock.

A number of research firms have issued reports on BSX. Stifel Nicolaus restated a “buy” rating and issued a $37.00 target price on shares of Boston Scientific in a report on Thursday, July 26th. Jefferies Financial Group restated a “hold” rating and issued a $34.00 target price on shares of Boston Scientific in a report on Thursday, July 26th. Guggenheim restated a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a report on Friday, July 27th. ValuEngine upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Monday, June 11th. Finally, Morgan Stanley upped their target price on shares of Boston Scientific from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $34.95.

In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $33.66, for a total value of $168,300.00. Following the completion of the transaction, the executive vice president now owns 29,201 shares in the company, valued at approximately $982,905.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Eric Francis Yves Thepaut sold 20,015 shares of the company’s stock in a transaction that occurred on Thursday, May 17th. The stock was sold at an average price of $30.15, for a total value of $603,452.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 157,986 shares of company stock valued at $5,244,475. 0.73% of the stock is owned by company insiders.

NYSE BSX opened at $33.55 on Friday. The company has a market capitalization of $47.42 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 2.51 and a beta of 0.65. Boston Scientific Co. has a fifty-two week low of $24.54 and a fifty-two week high of $37.30. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.83 and a quick ratio of 0.60.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.07. The firm had revenue of $2.49 billion during the quarter, compared to analysts’ expectations of $2.47 billion. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. Boston Scientific’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 EPS. sell-side analysts forecast that Boston Scientific Co. will post 1.38 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.